Chagas Disease, caused by the T. cruzi parasite, is one of the largest public health problems in the Western hemisphere. Although its spread has diminished due to vector eradication programs, effective chemotherapeutics for the disease itself remain elusive. Many efforts towards the development of antiparasitic agents active against a number of targets have been described recently in the literature. This review summarizes developments in trypanosidal agents from 2000 through 2003.
Keywords: parasitic disease, trypanosoma cruzi, autoimmunity, proinflammatory, t cells, chemotherapeutics, gycolysis, glyceraldehyde-3-phosphate dehydrogenase (gadph)
Rights & PermissionsPrintExport